Current and future prospective of pharmaceutical manufacturing in Saudi Arabia
Saudi Pharmaceutical Journal · 2023-04 · 31 (4) · 605-616
DOI: 10.1016/j.jsps.2023.03.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Saudi Pharmaceutical Journal, 2023-04. Verfasst von Sultan Alshehri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University, AlMaarefa University.
Abstract (Originalsprache)
This observational descriptive study that was carried out with the objective of exploring the contribution of the local pharmaceutical industry to the Saudi drug security. Using a drug formulary provided from the Saudi Food and Drug Authority, containing all registered pharmaceutical products available in Saudi Arabia, we extracted information about drug class, drug type, country and place of manufacturing, shelf-life and price. Results showed that the majority of drugs in the market are manufactured in Europe (43.86%), followed by Saudi Arabia (22.55%), China and India (20.47%), Americas (10.24%), and other nations (2.61%). Most of the manufactured drugs were prescription drugs (90.62%). In this work, the local pharmaceutical industry with the highest percentage of contribution to local drug security was Pharmaceutical Solution Industries (PSI), representing the 5% of the items available in the Saudi market. The second highest percentage was 4% by TABUK Pharmaceutical Manufacturing CO., followed by SPIMACO (3%), JAMJOOM pharmaceutical company (2%), Riyadh pharma (2%), and Jazeera pharmaceutical industries (2%). In addition, results from this study provide information about the most essential pharmaceutical products that needs to be nationally manufactured or increased in production in order to rise the contribution of local pharmaceutical industries in Saudi drug security. Unfortunately, the small contribution of the Saudi pharmaceutical industry in local drug security increases the burden on the Kingdom's annual budget due to the over-reliance on international pharmaceuticals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.
- Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Saudi Food and Drug Authority, Drug Sector, Riyadh, Saudi Arabia.
Förderung
- King Saud University
- AlMaarefa University
Zitieren
APA
Alshehri, S., Alshammari, R., Alyamani, M., Dabbagh, R., Almalki, B., Aldosari, O., Alsowayigh, R., Alkudeer, A., Aldosari, F., Sabr, J., & Shakeel, F. (2023). Current and future prospective of pharmaceutical manufacturing in Saudi Arabia. Saudi Pharmaceutical Journal, 31(4), 605-616. https://doi.org/10.1016/j.jsps.2023.03.001
Vancouver
Alshehri S, Alshammari R, Alyamani M, Dabbagh R, Almalki B, Aldosari O, et al. Current and future prospective of pharmaceutical manufacturing in Saudi Arabia. Saudi Pharmaceutical Journal. 2023;31(4):605-616. doi:10.1016/j.jsps.2023.03.001
BibTeX
@article{Alshehri2023,
author = {Alshehri, Sultan and Alshammari, Rehab and Alyamani, Mohammad and Dabbagh, Rufaidah and Almalki, Bander and Aldosari, Omamah and Alsowayigh, Renad and Alkudeer, Amirah and Aldosari, Fatimah and Sabr, Jumana and Shakeel, Faiyaz},
title = {Current and future prospective of pharmaceutical manufacturing in Saudi Arabia},
journal = {Saudi Pharmaceutical Journal},
year = {2023},
volume = {31},
number = {4},
pages = {605--616},
doi = {10.1016/j.jsps.2023.03.001}
}
EUVIMED